As growing interactions with FDA signal a surge in applications for continuous manufacturing of pharmaceuticals, early adopters of this technological alternative to traditional batch processing are advising the next wave of applicants to meet early and often with the agency.
The status of continuous manufacturing as well as some strategies for getting applications approved worldwide were discussed June 7 at an International Society for